Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5362
Gene Symbol: PLXNA2
PLXNA2
CUI: C0017921
Disease: Glycogen storage disease type II
Glycogen storage disease type II
0.060 Biomarker BEFREE Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF. 29567794

2019

Entrez Id: 5362
Gene Symbol: PLXNA2
PLXNA2
CUI: C0017921
Disease: Glycogen storage disease type II
Glycogen storage disease type II
0.060 Biomarker BEFREE This pilot study demonstrates that the vascular pattern of CNV in AMD can be visualized and described using mathematical parameters of OCT-A. 30971814

2019

Entrez Id: 5362
Gene Symbol: PLXNA2
PLXNA2
CUI: C0017921
Disease: Glycogen storage disease type II
Glycogen storage disease type II
0.060 Biomarker BEFREE Semivariogram and Semimadogram functions as descriptors for AMD diagnosis on SD-OCT topographic maps using Support Vector Machine. 30352604

2018

Entrez Id: 5362
Gene Symbol: PLXNA2
PLXNA2
CUI: C0017921
Disease: Glycogen storage disease type II
Glycogen storage disease type II
0.060 Biomarker BEFREE The macular thickness measurements generated by the two instruments in eyes with AMD differed significantly in mean retinal thickness in the foveal center subfield (257.34 μm ± 51.72 μm using the Nidek OCT vs. 238.20 μm ± 51.89 μm using the Cirrus OCT; P < .001). 29927468

2018

Entrez Id: 5362
Gene Symbol: PLXNA2
PLXNA2
CUI: C0017921
Disease: Glycogen storage disease type II
Glycogen storage disease type II
0.060 Biomarker BEFREE Since the advent of optical coherence tomography angiography (OCT-A), nonexudative neovascularization has been described in the fellow eyes of unilateral exudative age-related macular degeneration (AMD). 29879284

2018

Entrez Id: 5362
Gene Symbol: PLXNA2
PLXNA2
CUI: C0017921
Disease: Glycogen storage disease type II
Glycogen storage disease type II
0.060 GeneticVariation BEFREE Clinical, funduscopic and OCT characteristics of 194 treatment-naïve patients with AMD treated with as-needed ranibizumab for at least 2 years and up to 4 years were analyzed at baseline, 3 months and each year until the end of the follow-up. 28821236

2017